Specifically, the in vivo results demonstrated that in a murine melanoma model, the intratumoral infusion of alum-tethered IL-12 exhibited retention for weeks in the tumors along and induced minimal side effects while inducing substantial IFN-γ-mediated NK and T lymphocyte activity, thus increasing tumor antigen accumulation in draining lymph nodes and triggering strong tumor-specific T-cell priming (146). The gene discussed is IFNG; the disease is neoplasm.